Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 492 participants.

Also called NCT04734353

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 492 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04734353
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04734353. Randomized; no masking; primary purpose treatment. Start 2020-01-15 (actual); primary completion 2021-06-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
Acronym
E-5TION
Intervention (Drug)
Prasugrel 5mg
Intervention (Drug)
Ticagrelor 60mg
Lead sponsor
Gyeongsang National University Hospital (class: other)
Collaborator
U&I Corporation (class: other)

Record details

Record id
cardio:ct-nct04734353
Content hash
8c00e57cc7ffc53049fccfa00eb5088be37c70a6f541d70359bab9638f8e476f